These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 18510103)

  • 41. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient exploration of chemical space by fragment-based screening.
    Hall RJ; Mortenson PN; Murray CW
    Prog Biophys Mol Biol; 2014; 116(2-3):82-91. PubMed ID: 25268064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fragment-based drug discovery: concept and aim].
    Tanaka D
    Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.
    Di Lello P; Pastor R; Murray JM; Blake RA; Cohen F; Crawford TD; Drobnick J; Drummond J; Kategaya L; Kleinheinz T; Maurer T; Rougé L; Zhao X; Wertz I; Ndubaku C; Tsui V
    J Med Chem; 2017 Dec; 60(24):10056-10070. PubMed ID: 29166018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fragment-Based Drug Discovery for RNA Targets.
    Lundquist KP; Panchal V; Gotfredsen CH; Brenk R; Clausen MH
    ChemMedChem; 2021 Sep; 16(17):2588-2603. PubMed ID: 34101375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting the success of fragment screening by X-ray crystallography.
    Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ
    Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Fragment-Based Approach for the Development of G-Quadruplex Ligands: Role of the Amidoxime Moiety.
    Tassinari M; Lena A; Butovskaya E; Pirota V; Nadai M; Freccero M; Doria F; Richter SN
    Molecules; 2018 Jul; 23(8):. PubMed ID: 30060461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fragment-based drug discovery: what has it achieved so far?
    Alex AA; Flocco MM
    Curr Top Med Chem; 2007; 7(16):1544-67. PubMed ID: 17979767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design of screening collections for successful fragment-based lead discovery.
    Na J; Hu Q
    Methods Mol Biol; 2011; 685():219-40. PubMed ID: 20981526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fragment-based approach to drug lead discovery: overview and advances in various techniques.
    Fattori D; Squarcia A; Bartoli S
    Drugs R D; 2008; 9(4):217-27. PubMed ID: 18588353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In silico fragment-based drug design with SEED.
    Marchand JR; Caflisch A
    Eur J Med Chem; 2018 Aug; 156():907-917. PubMed ID: 30064119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integration of fragment screening and library design.
    Siegal G; Ab E; Schultz J
    Drug Discov Today; 2007 Dec; 12(23-24):1032-9. PubMed ID: 18061882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.
    Albert JS; Blomberg N; Breeze AL; Brown AJ; Burrows JN; Edwards PD; Folmer RH; Geschwindner S; Griffen EJ; Kenny PW; Nowak T; Olsson LL; Sanganee H; Shapiro AB
    Curr Top Med Chem; 2007; 7(16):1600-29. PubMed ID: 17979771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.